Key takeaway: Aurobindo Pharma Limited's investor presentation reported key financial highlights for Q1 FY27, showing a revenue of ₹9,150 Cr, reflecting a 16.3% year-on-year growth. The EBITDA was ₹1,924 Cr, with a margin of 21.0%, and net profit reached ₹1,032 Cr, marking a 25.2% increase compared to the previous year. The U.S. market contributed significantly, with revenue from U.S. formulations accounting for 41.2% of total revenue. The company launched 10 products in the U.S. during the quarter and received final approval for an equal number. Additionally, the presentation provided updates on biosimilars and biologics contract manufacturing, highlighting regulatory achievements and commercial expansions in various regions. Aurobindo also reported a strong cash flow position despite significant capital expenditures related to acquisitions and buybacks.

Key takeaway: Aurobindo Pharma Limited reported strong financial results for Q4 FY26 and the full year, with revenues reaching ₹33,653 crores and EBITDA at ₹6,856 crores, reflecting a healthy EBITDA margin of 20.4%. For Q4 FY26, revenues were ₹8,853 crores, with EBITDA at ₹1,801 crores and a margin of 20.3%. Management highlighted growth across various business segments, including a 30% year-on-year increase in European formulations. The company noted a 2% year-on-year increase in net profit to ₹921 crores. Management discussed ongoing strategic initiatives, including expansion in the U.S. and Europe, and emphasized the importance of their diversified product portfolio. They set a goal for EBITDA margins to improve to over 21% in FY27. The earnings call included a Q&A session addressing operational costs, product launches, and future growth strategies.

Key takeaway: Aurobindo Pharma Limited's investor presentation reported key financial highlights for Q4FY26, including revenue of ₹8,853 crores, reflecting a 5.6% year-on-year growth, and a net profit of ₹921 crores, which showed a 2.0% increase compared to the previous year. The presentation highlighted strong performance in Europe and stable results in the US market, despite a decline in transient product sales. Management noted a net capital expenditure of US$ 82 million focused on capability enhancements and new business developments. The company generated free cash flows of $35 million during the quarter, maintaining a strong net cash position of approximately US$ 317 million as of March 31, 2026. Additionally, the update on biosimilars indicated progress with approvals and partnerships aimed at expanding their market presence. The document also included a financial summary and a snapshot of regulatory filings.

Key takeaway: Aurobindo Pharma Limited reported an 8.4% year-on-year growth in consolidated revenue for Q3 FY26, reaching 8,646 crores, driven by strong performance in European operations and stable U.S. business. The EBITDA for the quarter was 1,773 crores, with a margin of 20.5%, reflecting a 9% year-on-year increase. The overall formulation business grew by 10%, contributing 89% of total revenue. U.S. revenue was reported at USD 420 million, with a 17% year-on-year growth in injectable sales. The European business saw a 27% revenue increase, while growth markets remained flat. Management highlighted the ramp-up of the Pen-G facility and the positive impact of government policy changes on domestic manufacturing. The company expressed confidence in sustaining growth momentum and achieving long-term value creation through strategic initiatives and operational excellence.

Key takeaway: Aurobindo Pharma Limited's investor presentation reported key financial highlights for Q3FY26, showing a revenue of ₹8,646 crores, reflecting an 8.4% year-on-year growth. The EBITDA was reported at ₹1,773 crores with a margin of 20.5%, driven by stable gross margins and operational efficiencies. The company generated free cash flows of $118 million during the quarter, maintaining a strong net cash position of approximately $251 million after accounting for the Khandelwal Labs acquisition. The presentation also highlighted the company's performance in the US and Europe, with US revenue accounting for 43.2% of consolidated revenue and Europe showing a 27.4% year-on-year growth. Additionally, Aurobindo provided updates on its biosimilars pipeline, indicating ongoing development and regulatory progress in various markets. The document emphasized the company's strategic focus on expanding its biosimilars portfolio and enhancing operational capabilities.

Key takeaway: Aurobindo Pharma Limited's investor presentation reported key financial highlights for Q3FY26, showing a revenue of ₹8,646 crores, reflecting an 8.4% year-on-year growth. The EBITDA was reported at ₹1,773 crores with a margin of 20.5%, driven by stable gross margins and operational efficiencies. The company generated free cash flows of $118 million during the quarter, maintaining a strong net cash position of approximately $251 million after accounting for the Khandelwal Labs acquisition. The presentation also highlighted the company's performance in the US and Europe, with the US market contributing 43.2% to consolidated revenue and Europe showing a 27.4% year-on-year growth. Aurobindo's biosimilars segment is advancing with a robust pipeline, including two products in Phase 3 studies, and plans for regulatory submissions in 2026. The document emphasized ongoing strategic initiatives and partnerships to enhance commercialization and expand market reach.